RCS - Hikma Pharmaceutical - Hikma reaches licensing agreement with Celltrion <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/12/2017 09:00

RNS Number : 6681Z
Hikma Pharmaceuticals Plc
19 December 2017
PRESS RELEASE
Hikma reaches licensing agreement with Celltrion for third biosimilar product in the Middle East and North Africa 
London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-basedCelltrion, Inc. andCelltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncologyto be granted European marketing authorisation, Truxima (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima (rituximab), Remsima (infliximab) and Herzuma (trastuzumab) - in all its MENA markets. 
Truxima is mAb biosimilar to Roche's MabThera (rituximab), which is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. 
Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima (rituximab) in all of its MENA markets, leveraging Hikma's strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, "We are pleased to be adding Truxima to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines."
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and Director of Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Virginia Spring
Investor Relations Manager
+44 (0)20 3892 4389/ +44 7973 679502
FTI Consulting
Ben Atwell/Brett Pollard
+44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'Injectables,' 'Generics' and 'Branded,' based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAGGGGAPUPMGPR